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OBJECTIVES This phase I trial was designed to assess the feasibility and safety of autologous skeletal
myoblast transplantation in patients with severe ischemic cardiomyopathy.
BACKGROUND Experimentally, myoblast grafting into postinfarction myocardial scars improves left ventric-
ular function.
METHODS Ten patients were included on the basis of the following criteria: 1) severe left ventricular
dysfunction (ejection fraction 35%); 2) the presence of a postinfarction akinetic and
nonviable scar, as assessed by dobutamine echocardiography and 18-fluorodeoxyglucose
positron emission tomography; and 3) an indication of coronary bypass in remote areas.
Skeletal myoblasts were grown from a biopsy taken at the thigh.
RESULTS An average of 871  106 cells (86% of myoblasts) were obtained after a mean period of 16
days and implanted uneventfully across the scar at the time of bypass. Except for one patient
whose early death was unrelated to the cell transplantation, all patients had an uncomplicated
postoperative course. Four patients showed delayed episodes of sustained ventricular tachy-
cardia and were implanted with an internal defibrillator. At an average follow-up of 10.9
months, the mean New York Heart Association functional class improved from 2.7  0.2
preoperatively to 1.6  0.1 postoperatively (p  0.0001), and the ejection fraction increased
from 24 1% to 32 1% (p 0.02). A blinded echocardiographic analysis showed that 63%
of the cell-implanted scars (14 of 22) demonstrated improved systolic thickening. One
noncardiac death occurred 17.5 months after transplantation.
CONCLUSIONS These preliminary data suggest the feasibility and safety of autologous skeletal myoblast
transplantation in severe ischemic cardiomyopathy, with the caveat of an arrhythmogenic
potential. New-onset contraction of akinetic and nonviable segments suggests a functional
efficacy that requires confirmation by randomized studies. (J Am Coll Cardiol 2003;41:
1078–83) © 2003 by the American College of Cardiology Foundation
Heart failure is a major and expanding public health
concern; in most cases, it results from myocardial infarction,
leading to an akinetic fibrous scar and associated left
See page 1084
ventricular (LV) remodeling. Despite dramatic improve-
ments in the medico-surgical management of these patients,
their persistently dismal outlook (1) still justifies the ongo-
ing search for new treatments.
In this setting, cellular transplantation is receiving a
growing interest as a means of replacing lost cardiomyocytes
by exogenously supplied contractile cells, among which the
skeletal myoblasts, which are responsible for skeletal muscle
formation and repair, feature clinically attractive character-
istics, including ease of procurement, growth potential in
vitro, and strong resistance to ischemia.
Experimentally, engrafted skeletal myoblasts differentiate
into myotubes and improve postinfarction cardiac function
(2–8). These observations have set the stage for this phase
I human trial in which the first patient was operated on June
15, 2000 (9).
METHODS
Inclusion criteria. Eligibility for inclusion was based on: 1)
systolic LV dysfunction, as reflected by an echocardio-
graphic LV ejection fraction (LVEF) 35%; 2) a history of
myocardial infarction with a residual akinetic and nonviable
scar, as demonstrated by a lack of response to low-dose
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dobutamine echocardiography and of metabolic activity on
fluorine-18 fluorodeoxyglucose (18FDG) positron emission
tomography (PET); and 3) an indication for concomitant
coronary artery bypass graft (CABG) in remote (i.e., differ-
ent from the transplanted area) and viable but ischemic
myocardium. The main exclusion criteria consisted of dia-
betes, cardiogenic shock, unstable angina requiring urgent
surgery, peripheral muscular dystrophy, and positive sero-
logic test results for human immunodeficient virus and
hepatitis.
This protocol was approved by the French Regulatory
Health Authorities and our ethics committee. Patients were
included after having received extensive information and
giving their witnessed consent.
Preoperative screening. Transthoracic two-dimensional
echocardiography was performed using fundamental and
second-harmonic imaging. Global LVEF (%) was calculated
from measurements of LV end-diastolic volume (LVEDV)
and LV end-systolic volume (LVESV; both in ml) using the
biplane Simpson’s rule, as ([LVEDV LVESV]/LVEDV)
 100 (10). Regional contractile function was assessed
semiquantitatively after division of the LV into 16 seg-
ments, as recommended by the American Society of Echo-
cardiography (10). Care was taken to optimize endocardial
visualization on three parasternal short-axis views of the LV
(at the base, mid-ventricular level, and apex) and apical
two-, three-, and four-chamber views. Segmental thicken-
ing of each segment was then visually evaluated and graded
as dyskinetic, akinetic, severely hypokinetic, moderately
hypokinetic, or normal (11). This initial assessment was
performed within the month before surgery, not during
episodes of cardiac failure, and at rest; and dobutamine (5,
10, and 15 g/kg per min without exceeding a 10-beats/min
increase in heart rate) was used to check for the absence of
induced segmental thickening in the infarcted area (12,13).
The 18FDG PET studies were performed with a whole-
body scanner (ECAT Exact, CTI/Siemens, Knoxville, Ten-
nessee) with an intrinsic spatial resolution of 6 mm full
width at half maximum. To augment myocardial glucose
uptake, each patient received 50 g of glucose orally. One
hour later, 18FDG (370 MBq) was injected intravenously
and six images of 5 min each were acquired after 13 min.
The relative regional myocardial 18FDG uptake was deter-
mined on three short-axis slices that corresponded in
location to the echocardiographic sections and to the sur-
gical map depicting the sites of cell injections. Regional
myocardial 18FDG activity concentrations were defined as
the ratio over the maximum myocardial 18FDG uptake.
Segments with 50% 18FDG uptake were defined as
nonviable (14).
Staging of the procedure. MUSCULAR BIOPSY. A 10- to
15-g piece of the vastus lateralis muscle was retrieved from
the patient’s thigh under local anesthesia, minced, and
transported in a preservation medium to the Cell Therapy
Laboratory.
CELL CULTURES. The general methodology has been pre-
viously described (9). Briefly, the muscle biopsy was di-
gested using collagenase and trypsin. The primary cell
culture was expanded in cell factories using a clinical grade
myogenic-specific medium based on a modification of
MCDB120, supplemented with bovine fetal serum, basic
fibroblast growth factor, dexamethasone, penicillin, and
streptomycin. The cells were expanded and harvested before
reaching confluency by trypsinization. Scale-up was per-
formed to achieve the following targets: at least 500  106
cells, 50% myoblasts, and 70% viable cells. Finally, cells
were collected by trypsinization, washed, and suspended in
albumin (150  106 cells/ml). Quality control was per-
formed throughout the process and for the final product.
The percentage of myoblasts and viable cells was quantified
by flow cytofluorimetry after staining for CD56, a marker
specific for skeletal muscle cells, and upon exclusion of
propidium iodide, respectively. Preclinical double-labeling
fluorocytometric analyses have demonstrated that most
CD56-positive cells were also positive for desmin. Short-
and long-term microbiologic control studies were per-
formed repeatedly. The cell-containing suspension was
transferred into sterile syringes, which were shipped back at
room temperature to the cardiac surgery department. One
aliquot of the final product was retained for testing the
myogenic capacity of the cells, and, in the first five patients,
another aliquot was used for tumorigenic testing by inject-
ing 5  105 cells intravenously into irradiated nonobese
diabetic-severe combined immunodeficient mice.
CELL TRANSPLANTATION. Under cardioplegic arrest, the
cell suspension was injected within and around the scar,
using a customized prebent 27-gauge needle, allowing
tangential injections and thus reducing the risk of intracav-
itary cell delivery.
There was no specific postoperative treatment except for
corticosteroids (prednisolone, 780 mg), given over the first
two postoperative days.
Assessment of outcomes. The primary end points were
feasibility and safety. Feasibility was defined as the ability of
the expansion procedure to yield the target numbers of cells
within two to three weeks. Safety referred to adverse events
related to biopsy/cell reimplantation and specifically in-
volved detection of ventricular arrhythmias by 24-h Holter
Abbreviations and Acronyms
AICD  automatic internal cardioverter-defibrillator
CABG  coronary artery bypass graft
18FDG  fluorine-18–labeled fluorodeoxyglucose
LV  left ventricle/ventricular
LVEDV  left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
NYHA  New York Heart Association
PET  positron emission tomography
VT  ventricular tachycardia
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electrocardiographic (ECG) monitoring studies performed
before and within the first three postoperative months.
The secondary end point was efficacy, which was primar-
ily assessed by two-dimensional echocardiographic analysis
of LV function at one, three, and six months postoperatively
and at the end of follow-up. In addition to measurements of
global LVEF, serial changes in LV segmental thickening
were evaluated semiquantitatively and classified as un-
changed, improved (1 grade), or worsened (1 grade).
These grafted areas were localized by reference to the
intraoperative diagram depicting the injection sites. Image
analysis was performed by two investigators, one of whom
was blinded to the timing of echocardiography, the number
and location of coronary bypasses, and the sites of cell
injections.
Statistics. Results are reported as the mean value  SEM.
A comparison of preoperative and postoperative data was
done using the paired t test, with p  0.05 as the limit of
significance.
RESULTS
Study group. The study group (Table 1) comprised 10
male patients with a mean age of 60  3 years (range 38 to
73). The age of the infarct was 6.2  1.9 years (range 1
month to 19 years), and its location was anterior (n  6),
posterior (n  3), or posterolateral (n  1). All of the
infarcted areas were angiographically subserved by totally
occluded, nonrevascularizable coronary arteries.
All patients had evidence of myocardial ischemia, as
demonstrated by angina or stress tests, and/or clinical
symptoms of congestive heart failure. Four patients were in
New York Heart Association (NYHA) functional class II;
five in class III; and one in class IV. The LVEF was 24.3 
1.3% (range 18% to 34%), and the 18FDG uptake ratio was
0.41  0.04.
Cell cultures. Histologic analysis of the biopsied muscle
revealed normal anatomy. The target numbers of cells were
consistently achieved in all patients within two to three
weeks (i.e., 953  71  106 cells [range 530 to 1,215] were
produced in 16  1 days [range 14 to 20]). All cultures
contained more than 60% myogenic cells (mean 86  3%
[range 67% to 97%]) and more than 90% viable cells (mean
95  1% [range 86% to 99%]). There was no bacterial or
fungal contamination. None of the NOD-SCID mice
injected with myoblasts developed a macroscopically detect-
able tumor. Myoblasts that were replated at the time of final
cell collection grew to confluency and then differentiated
and fused to form multinucleated myotubes characteristic of
skeletal muscle tissue.
Cell transplantation. All patients had two bypass grafts
except for one patient who had three. An average volume of
5.7  0.3 ml (range 4 to 8) containing 871  62  106
(range 500 to 1,115) was injected in 37  3 sites (range 27
to 57) throughout the scar area (29  3 cm2 [range 20 to
40]). The procedure averaged 18  1 min (range 15 to 26)
and was consistently uneventful.
Early postoperative course. There was no complication
related to the muscular biopsy. One patient (no. 5) in
NYHA class IV with a history of three previous infarctions
died early after the operation, likely due to a mesenteric
infarction subsequent to a profound hemodynamic deterio-
ration, which occurred suddenly before cardiopulmonary
bypass was instituted. The postoperative course of the other
nine patients was uneventful.
Short-term outcomes. By April 1, 2002, the follow-up
period averaged 10.9  4.5 months (range 5 to 17.5).
The only adverse event likely related to the procedure was
the occurrence of sustained, monomorphic ventricular
tachycardia (VT) featuring a right conduction delay pattern
in four patients, three of whom had preoperative ventricular
hyperexcitability (grade 2 to 3 in Lown’s classification). All
these VTs occurred early after the operation (11 to 22 days)
and, except for one syncopal form, were clinically well
tolerated. None of these arrhythmias occurred in the setting
Table 1. Patient Data
Patient
No.
Age
(yrs)
Myocardial Infarct
NYHA
Class
Cell Transplantation
Location of
Bypass Grafts
LVEF (%)
Age Location
No. of Cells
Injected (106)
CD56
(%)
No. of
Injections PreTx PostTx*
1 72 2 years Posterior III–IV 820 67 33 LAD  Dg 20 35
2 66 6 years Anterior III 870 91 50 OM (2) 25 27
3 67 9 and 3 years Posterior II 620 97 57 LAD  OM 31 41
4 39 4 months Posterolateral II 950 95 31 LAD  IA 22 45
5 55 7 years and
5 and 3 months
Anterior III–IV 1,150 85 42 RCA  IA 34 NA†
6 52 5 years Posterior III 880 96 36 LAD  IA 26 30
7 73 14 months Anterior III 980 92 34 RCA  IA 28 32
8 69 3 months Anterior II 1,100 85 35 RCA  Dg 25 29
9 51 19 years and
1 month
Anterior II 500 75 27 OM  PLA  PDA 18 25
10 67 13 years Anterior III 840 81 31 OM  IA 24 25
*As assessed at the time of the last follow-up visit. †Early postoperative death.
Dg  diagonal artery; IA  intermediate artery; LAD  left anterior descending coronary artery; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association; OM  obtuse marginal branch; PDA  posterior descending artery; PLA  posterior lateral artery; RCA  right coronary artery; Tx  transplantation
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of myocardial ischemia, which was consistently ruled out by
the absence of suggestive clinical and ECG changes and full
angiographic patency of all grafts. The four patients were
implanted with an automatic internal cardioverter-
defibrillator (AICD), either shortly after the operation
because of the inducibility of VT on programmed ventric-
ular stimulation (n  2; Patient nos. 7 and 8) or later
(Patient nos. 4 and 6) because of a delayed recurrence of VT
(at five and nine months postoperatively), despite antiar-
rhythmic drug therapy (beta-blockers and amiodarone).
Among the two patients who had late device implantation,
only one had undergone an early postoperative stimulation,
which failed to induce VT. At follow-up after AICD
implantation (one month in one case and eight months in
the other three cases), only one of the four device-implanted
patients had experienced two appropriate shocks. In the last
three patients in the trial, amiodarone therapy was prophy-
lactically instituted at the time of biopsy and continued for
three months. One patient still experienced asymptomatic
VT (he is one of those who received an early postoperative
defibrillator), but at the time of the latest follow-up visit, the
two others had remained arrhythmia-free. The small size of
the sample did not allow us to conclusively establish a
correlation between the number of injected cells and the
occurrence of VT.
Efficacy data pertain to eight of the nine operative
survivors, as the poor echogenicity of Patient no. 7 led to his
exclusion from further segmental analysis by the blinded
observer. For these eight patients, there was complete
agreement between the two observers regarding the post-
operative improvement in systolic thickening 1 grade. In
this cohort, LVEF rose from 23.8  3.9% (range 18% to
31%) preoperatively to 32.1  7.5% (range 25% to 45%)
postoperatively (p  0.02), whereas LVEDV remained
statistically unchanged (124  46 ml/m2 [range 56 to 154]
postoperatively vs. 107  31 ml/m2 [range 69 to 198]
preoperatively). According to the surgical map, 22 in-scar
segments were implanted with cells. Postoperatively, 14 of
them (63%) demonstrated new-onset echocardiographic
systolic shortening (6 of 8 patients), with the number of
improved segments increasing over time (from 8 before 3
months to 14 at the end of follow-up). In comparison, 26
noninjected but revascularized segments improved echocar-
diographically to a similar extent as the grafted ones after
the procedure. This amelioration translated into an im-
provement in NYHA class from 2.7  0.2 to 1.6  0.1 (p
 0.0001), whereas preoperative medications were contin-
ued unchanged after surgery, except for diuretics, the dose
of which was tailored to the magnitude of congestive
symptoms. Only one patient required a brief rehospitaliza-
tion for a transient episode of heart failure related to
inadvertent discontinuation of diuretics. One patient (Pa-
tient no. 1) died of a stroke at 17.5 months postoperatively.
The improvement of his cardiac function (both global and
segmental), which was manifest early postoperatively, was
sustained thereafter until the time of his death. Autopsy
found clusters of myotubes embedded in the scar tissue,
without evidence of cardiomyogenic differentiation, as re-
flected by the lack of gap junction formation.
DISCUSSION
Feasibility. Our first objective was to assess whether cell
culture procedures routinely used experimentally could be
clinically upgraded so as to make them compatible with
human use. From this standpoint, the present results are
satisfactory, as a large number of cells could reproducibly be
grown from the initial muscle biopsy within two to three
weeks and in strict compliance with Good Manufacturing
Practice constraints. Because the functional outcome fol-
lowing myoblast transplantation is related to the number of
injected cells (15), the lower target cell yield was set at 500
 106, at least 50% of which were required to be myoblasts.
Our data show that these thresholds were consistently
overshot. Although it is technically possible to grow more
than one billion cells, such numbers would require larger
injection volumes, which raises a potential safety issue.
Reducing this volume by increasing the cell concentration
would, in turn, expose the cells to damage subsequent to
their passage through a necessarily small-bore needle.
Cultures were obtained expeditiously in all patients,
regardless of their age and comorbidities. Likewise, there
was little variability in the percentage of myogenic cells or
their functional capacity to form multinucleated myotubes
in vitro.
Safety. There were no perioperative complications related
to biopsy or cell injections. The two early and late deaths
were clearly unrelated to the cell transplantation procedure.
The absence of tumor in myoblast-injected immunode-
ficient mice confirms that oncogenicity is unlikely to be a
concern with autologous transplantation of primarily cul-
tured skeletal myoblasts. When these myoblasts were ex-
posed to the differentiation medium, they never turned to
cells of a different nature (i.e., osteoblasts, chondroblasts).
This commitment to a strictly myogenic lineage is due to
the already advanced stage of differentiation of myoblasts
and contrasts with the greater phenotypic plasticity of bone
marrow stem cells, which are also considered for intramyo-
cardial grafting.
The only serious adverse event likely related to the
procedure was the occurrence of ventricular arrhythmias in
four patients, although such a relationship may be con-
founded by the trend for patients with ischemic cardiomy-
opathies to develop arrhythmic events (16). Skeletal myo-
blasts and cardiomyocytes express different sets of ion
channels (17) whose distinct kinetic activation/inactivation
patterns could result in arrhythmogenic inhomogeneities in
action potential conduction. In fact, inhomogeneous in-
tramyocardial distribution of gap junctions increases the risk
of arrhythmias (18). Alternatively, these arrhythmias could
have an inflammatory origin due to both needle punctures
and early cell death from necrosis and/or apoptosis, as
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shown in other models of cell transplantation (19,20). These
events would then trigger the release of inflammatory
cell-derived arrhythmogenic products, as occurs during
myocarditis (21). Finally, reentry pathways could be created
by cell-independent, injection-related disorganization of the
supracellular myocardial anatomy in the border zone. These
various hypotheses are currently under experimental inves-
tigation.
In the four patients who experienced VT, the deci-
sion to implant a defibrillator was based on standard
transplantation-independent criteria and is consistent with
the survival benefit expected from the device in this patient
population at high risk of severe arrhythmic events, as
shown by the recently reported Multicenter Automatic
Defibrillator Implantation Trial (MADIT) II trial (22).
Efficacy. This phase I trial was neither designed nor pow-
ered to assess the efficacy of the procedure, so only careful
and preliminary conclusions can be drawn from the com-
parison of postoperative versus preoperative data.
As improvement in symptoms and LVEF may simply
reflect efficacious revascularization, analysis of echocardio-
grams primarily focused on contractile changes of the
cell-transplanted scarred segments. Fourteen of 22 of these
segments had improved kinetics, as evidenced by new-onset
systolic thickening. Experimentally, myoblast transplanta-
tion limits postinfarction ventricular dilation (23), but this
mechanism was probably not operative in our patients with
old infarctions and already enlarged ventricular dimensions
that did not regress postoperatively. Echocardiographic data
rather suggest a contribution of engrafted myotubes to
contractile function. As these cells do not express connexin
43–supported gap junctions with host cardiomyocytes (24),
classic electromechanical coupling is unlikely. However,
skeletal myoblasts could respond mechanically to the con-
traction of surrounding host cardiomyocytes to which they
may be bound through the extracellular matrix (25). Alter-
natively, engrafted myoblasts may release growth factors,
particularly insulin-like growth factor-1, with a subsequent
paracrine recruitment of cardiac stem cells (26) that would
promote a new endogenous pool of contractile cells.
Study limitations. A first limitation pertains to the semi-
quantitative approach used for assessing segmental function.
Although two-dimensional echocardiography has become
the technique of choice for direct visualization of endocar-
dial motion and wall thickening (27), this assessment may
still be confounded by contractile changes of the adjacent
segments, as long as myocardial strain is not directly
measured. The improved kinetics of the revascularized
segments could therefore have skewed the grading of
transplanted areas.
A second limitation is the possible confounding effect of
concomitant CABG. Two lines of reasoning, however,
temper this concern. First, 18FDG glucose uptake 50%
relative to that of the area of maximal tracer uptake, which
defines nonviable scar tissue (14,28), and the lack of
contractile response to low-dose dobutamine are both pre-
dictable of functional recovery after revascularization, with a
negative predictive power in the range of 90% (11,29–32).
Thus, at most, 10% of the nonviable segments would have
been expected to improve following bypass alone (29–
31,33,34), which is in contrast to the observed improvement
rate of 63% following transplantation. Second, pathologic
studies have shown that nonviable myocardial areas are
primarily made of fibrosis (35), with 25% still viable
myocytes (36). Because at least 50% of a segment’s myocytes
need to be functionally viable to improve following revas-
cularization (36), it is conceivable that the contractile
elements that accounted for new-onset systolic thickening
of transplanted segments were derived from the grafted
myoblasts.
However, the extent to which the improved inotropism of
the transplanted segments contributed to the increase in
global LVEF remains uncertain. A critical determinant of
LVEF recovery is the number of segments with improved
wall motion, and this number needs to encompass more
than 20% of the LV for global function to improve (37).
Combined with revascularization, cell transplantation might
contribute to reach this threshold.
Conclusions. These data show that autologous skeletal
myoblast transplantation is a feasible and straightforward
procedure. Randomized trials are now required to further
characterize the risk/benefit ratio of this novel approach.
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